Our scientific leadership team brings decades of drug R&D experiences at leading pharmaceutical companies, along with a proven track record of delivering multiple marketed immuno-oncology and oncology drugs, as well as clinical candidates. We understand what it takes to advance a full pipeline of novel antibody drugs to treat cancer, autoimmune disorders and other unmet medical needs around the world.

As a pioneer in ultra-high-throughput phenotyping and genotyping single-cell analysis, we are enabling a paradigm shift in biotherapeutic discovery and development efforts. Our proprietary antibody screening CelliGO™ system combines with our Drug Intelligent Science (DIS™) to enable rapid identification of differentiated therapeutic molecules and significantly enhance clinical probability of success.

Building upon our internal proprietary translational capabilities for single cell immune profiling, we have engaged the world’s top clinical immunologists and oncologists to drive a clinical development strategy that better connects biological targets to patient characteristics. Our primary indication drivers are unmet medical needs and deep understanding of mechanisms of action.

We continue to establish strategic partnerships with leading pharmaceutical and biotechnology companies, as well as academic institutions to accelerate the development of novel R&D technology platforms and identification of innovative therapeutics to improve patient care. All of our collaborations are architected for speed and driven by our scientific strategy.

We are developing a robust pipeline of novel therapeutic antibodies to modulate multiple immune cell types, initially focused on regulatory T cells and Myeloid-derived suppressor cells, to combat cancer and autoimmune disorders. Currently, we are advancing 10 internal R&D programs, majority first-in-class, toward the clinic with multiple preclinical candidates demonstrating proof of concept in animal models.